CHEMICAL DERIVATIZATION OF THERAPEUTIC PROTEINS

被引：10

作者：

SMITH, RAG

DEWDNEY, JM

FEARS, R

POSTE, G

机构：

[1] SmithKline Beecham Pharmaceuticals, Epsom, Surrey KT18 5XQ, Great Burgh, Yew Tree Bottom Road

来源：

TRENDS IN BIOTECHNOLOGY | 1993年 / 11卷 / 09期

关键词：

D O I：

10.1016/0167-7799(93)90100-N

中图分类号：

Q81 [生物工程学（生物技术）]; Q93 [微生物学];

学科分类号：

071005 ; 0836 ; 090102 ; 100705 ;

摘要：

Despite major advances in redesigning and producing proteins through recombinant DNA technology, many therapeutic proteins are still produced by extraction from biological tissues or fluids, or from nonrecombinant microorganisms. Modification of such proteins, to improve potency and bioavailability and reduce immunogenicity, can only be carried out post-translationally by chemical-derivatization methods. Genetic- and chemical-modification methods are not mutually exclusive, however, and may be combined to optimize protein-engineering strategies, because chemical modification can introduce structural changes that are not encoded by DNA into both recombinant, and nonrecombinant proteins.

引用

页码：397 / 403

页数：7

共 35 条

[1]

ABUCHOWSKI A, 1977, J BIOL CHEM, V252, P3578

[2] A NEW PROCEDURE FOR THE SYNTHESIS OF POLYETHYLENE GLYCOL-PROTEIN ADDUCTS - EFFECTS ON FUNCTION, RECEPTOR RECOGNITION, AND CLEARANCE OF SUPEROXIDE-DISMUTASE, LACTOFERRIN, AND ALPHA-2-MACROGLOBULIN [J].